3D texture analyses within the substantia nigra of Parkinson's disease patients on quantitative susceptibility maps and R2∗ maps

ABSTRACT Iron accumulation in the substantia nigra (SN) is spatially heterogeneous, yet no study has quantitatively evaluated how the texture of quantitative susceptibility maps (QSM) and R2* might evolve with Parkinson's disease (PD) and healthy controls (HC). The aim of this study was to discriminate between patients with PD and HC using texture analysis in the SN from QSM and R2* maps. QSM and R2* maps were obtained from 28 PD patients and 28 HC on a clinical 3T MR imaging scanner using 3D multi‐echo gradient‐echo sequence. The first‐ and second‐ order texture features of the QSM and R2* images were obtained to evaluate group differences using two‐tailed t‐test. After correction for multiple comparisons, for the first‐order analysis, the susceptibility of SN from patients with PD was significantly greater (p=0.017) compared with the SN from HC. For the second‐order texture analysis, angular second moment, entropy, and sum of entropy showed significant differences in QSM (p<0.001) and R2* maps (p<0.01). In addition, correlation, contrast, sum of variance and difference of variance, significantly separated the subject groups in QSM maps (p<0.05) but not in R2* images. Receiver operating characteristic analysis showed that entropy and sum of entropy of the QSM maps in the SN yielded the highest performance for differentiating PD patients from HC (area under the curve=0.89). In conclusion, most first‐ and second‐ order QSM texture features successfully distinguished PD patients from HC and significantly outperformed R2* texture analysis. The second‐order texture features were more accurate and sensitive than first‐order texture features for classifying PD patients. HIGHLIGHTSMost QSM texture features successfully distinguished PD from HC and significantly outperformed the R2* texture analysis.Second‐order texture features were more accurate and sensitive than first‐order texture features for classifying PD patients.Entropy and SumEntrp of the QSM maps yielded the highest performance for differentiating PD patients from HC in the SN.AngScMom, entropy and SumEntrp showed high direction correlation for differentiating PD from HC both in QSM and R2* maps.

[1]  Xuemei Huang,et al.  Quantitative susceptibility mapping of the midbrain in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[2]  J S Thornton,et al.  9.4T MR microscopy of the substantia nigra with pathological validation in controls and disease. , 2017, NeuroImage. Clinical.

[3]  Yi Wang,et al.  Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: Validation and application to brain imaging , 2010, Magnetic resonance in medicine.

[4]  Y. Smith,et al.  Substantia Nigra , 2020, Definitions.

[5]  Pascal Spincemaille,et al.  Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping , 2013, Magnetic resonance in medicine.

[6]  J. Gore,et al.  Intravascular susceptibility contrast mechanisms in tissues , 1994, Magnetic resonance in medicine.

[7]  Torsten Rohlfing,et al.  MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping , 2011, NeuroImage.

[8]  Y Wang,et al.  Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping , 2016, American Journal of Neuroradiology.

[9]  Yi Wang,et al.  Quantitative susceptibility mapping (QSM) of white matter multiple sclerosis lesions: Interpreting positive susceptibility and the presence of iron , 2015, Magnetic resonance in medicine.

[10]  Min Zhang,et al.  Reducing the object orientation dependence of susceptibility effects in gradient echo MRI through quantitative susceptibility mapping , 2012, Magnetic resonance in medicine.

[11]  A. Graybiel,et al.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.

[12]  Dorothee P. Auer,et al.  The ‘Swallow Tail’ Appearance of the Healthy Nigrosome – A New Accurate Test of Parkinson's Disease: A Case-Control and Retrospective Cross-Sectional MRI Study at 3T , 2014, PloS one.

[13]  Jin Keun Seo,et al.  Quantitative Susceptibility Mapping (QSM) Algorithms: Mathematical Rationale and Computational Implementations , 2017, IEEE Transactions on Biomedical Engineering.

[14]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[15]  Y Wang,et al.  Usefulness of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson Disease , 2015, American Journal of Neuroradiology.

[16]  P N Karnauchow,et al.  Accuracy of clinical diagnosis. , 1982, Canadian Medical Association journal.

[17]  G. Wooten,et al.  UPDRS activity of daily living score as a marker of Parkinson's disease progression , 2009, Movement disorders : official journal of the Movement Disorder Society.

[18]  Ferdinand Schweser,et al.  Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study , 2012, NeuroImage.

[19]  Tian Liu,et al.  Intracranial calcifications and hemorrhages: characterization with quantitative susceptibility mapping. , 2013, Radiology.

[20]  R. Bowtell,et al.  Visualization of nigrosome 1 and its loss in PD , 2013, Neurology.

[21]  G. Perry,et al.  Sequestration of iron by Lewy bodies in Parkinson’s disease , 2000, Acta Neuropathologica.

[22]  Hisashi Tanaka,et al.  Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson's disease. , 2018, The British journal of radiology.

[23]  Yi Wang,et al.  Background field removal by solving the Laplacian boundary value problem , 2014, NMR in biomedicine.

[24]  R. Cusack,et al.  New Robust 3-D Phase Unwrapping Algorithms: Application to Magnetic Field Mapping and Undistorting Echoplanar Images , 2002, NeuroImage.

[25]  E. Haacke,et al.  Quantitative susceptibility mapping: current status and future directions. , 2015, Magnetic resonance imaging.

[26]  Chunshui Yu,et al.  3D texture analysis on MRI images of Alzheimer’s disease , 2011, Brain Imaging and Behavior.

[27]  Wen-Jing Li 李文静,et al.  Dose- and time-dependent α-synuclein aggregation induced by ferric iron in SK-N-SH cells , 2010, Neuroscience Bulletin.

[28]  Andreas Schäfer,et al.  High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease , 2012, Journal of magnetic resonance imaging : JMRI.

[29]  Yi Wang,et al.  Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map , 2012, NeuroImage.

[30]  Kemin Chen,et al.  Region‐specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping , 2015, Human brain mapping.

[31]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[32]  E Mark Haacke,et al.  Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. , 2015, Magnetic resonance imaging.

[33]  Bharathi,et al.  Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease. , 2007, Biochemical and biophysical research communications.

[34]  Wei Li,et al.  Susceptibility‐weighted imaging and quantitative susceptibility mapping in the brain , 2015, Journal of magnetic resonance imaging : JMRI.

[35]  Marguerite Wieler,et al.  Midbrain iron content in early Parkinson disease , 2008, Neurology.

[36]  C Strand,et al.  9.4 T MR microscopy of the substantia nigra with pathological validation in controls and disease , 2016, NeuroImage: Clinical.

[37]  Martyn N J Paley,et al.  MRI assessment of basal ganglia iron deposition in Parkinson's disease , 2008, Journal of magnetic resonance imaging : JMRI.

[38]  Ashley I Bush,et al.  Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics , 2016, Journal of neurochemistry.

[39]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[40]  Yi Wang,et al.  A novel background field removal method for MRI using projection onto dipole fields (PDF) , 2011, NMR in biomedicine.

[41]  Yi Wang,et al.  Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker , 2014, Magnetic resonance in medicine.